Today: 23 April 2026
Subscribe

MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

MSP Recovery (MSPR) surged as much as 40% in pre-market trading on November 17, 2025, reaching $0.62 after closing at $0.45 on Friday. The spike came amid heavy volume and no new company news, as traders responded to recent volatility, a late Q3 filing, and ongoing Nasdaq delisting risk. Market cap remains below $1 million, with the company facing a $1.56 billion net loss in 2024 and a $1.2 billion debt restructuring.
17 November 2025
··
Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Saab’s B-share jumped 5–6% to SEK 555 on Monday, nearing a 52-week high after the company announced a €3.1bn contract to supply 17 Gripen E/F fighter jets to Colombia. Year-to-date, the stock is up over 120%. Analysts flagged strong order momentum but warned the valuation looks stretched. Saab’s order backlog reached SEK 187bn at 2024 year-end, up from SEK 153bn a year earlier.
17 November 2025
····
Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium shares surged over 30% in premarket U.S. trading Monday, hitting as high as $8.20 on volume exceeding 12 million shares. The rally follows strong Q3 2025 results and a bullish lithium demand forecast from China’s Ganfeng Lithium. Sigma closed Friday at $6.06, up 2.7% on heavy volume. Lithium futures in Guangzhou jumped 9% after Ganfeng projected 30% demand growth in 2026.
17 November 2025
···
Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition, a new $179.99 mobile controller officially licensed for Xbox, is now available through Backbone, Microsoft, Amazon, and Best Buy. The device features full-size ALPS thumbsticks, Hall Effect triggers, two rear paddles, and supports both wired and wireless play across phones, PCs, TVs, and VR headsets. Early reviews highlight its premium build and deep Xbox Cloud Gaming integration.
17 November 2025
·
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Dragonfly Energy (DFLI) Stock Pops as Canaccord Hikes Price Target to $2.25 After Big Q3 Earnings Beat

Dragonfly Energy (DFLI) Stock Pops as Canaccord Hikes Price Target to $2.25 After Big Q3 Earnings Beat

Dragonfly Energy shares rose 4.8% to $0.81 Monday after Canaccord Genuity raised its price target to $2.25 and reiterated a Buy rating, citing a stronger balance sheet. The move followed Q3 results showing a narrower loss of –$0.20 per share versus expectations for –$0.71, with revenue up 26% to $16 million and gross margin expanding to 29.7%.
17 November 2025
··
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
Twin Vee PowerCats (VEEE) Stock Jumps in Premarket as Bahama Boats Roll Out: Latest News for 17 November 2025

Twin Vee PowerCats (VEEE) Stock Jumps in Premarket as Bahama Boats Roll Out: Latest News for 17 November 2025

Twin Vee PowerCats (NASDAQ: VEEE) jumped as much as 22% in pre-market trading Monday, hitting $2.15 before dropping to around $1.73 by early afternoon. The move followed recent news on Bahama Boat Works deliveries and Q3 results showing narrower losses. No new filings or press releases appeared Monday. Trading volume and volatility spiked despite no fresh catalyst.
17 November 2025
·
WeShop Holdings (NASDAQ: WSHP) Soars Again as Nasdaq Composite Adds New Social‑Commerce Stock – 17 November 2025 Update

WeShop Holdings (NASDAQ: WSHP) Soars Again as Nasdaq Composite Adds New Social‑Commerce Stock – 17 November 2025 Update

WeShop Holdings (NASDAQ: WSHP) surged as much as 95% in pre-market trading on November 17, reaching nearly $60 after a 92% jump on its debut Friday. The stock was added to the Nasdaq Composite Index just days after listing. Pre-market volume topped 32,000 shares, with market cap estimates near $1.03 billion. Trading feeds showed extreme volatility, with prices fluctuating between $47 and $60.
17 November 2025
··
Cypherpunk Technologies (CYPH) Soars Over 300% on Zcash Pivot – What’s Driving Today’s Volatile Rally? (17 November 2025)

Cypherpunk Technologies (CYPH) Soars Over 300% on Zcash Pivot – What’s Driving Today’s Volatile Rally? (17 November 2025)

Cypherpunk Technologies (NASDAQ: CYPH) shares jumped over 30% in U.S. pre-market trading Monday, reaching about $3.60 and a $155 million market cap. The move follows last week’s rebrand from Leap Therapeutics and a $50 million Zcash purchase backed by Winklevoss Capital. CYPH stock has surged more than 300% since its Nasdaq debut under the new ticker on November 13.
17 November 2025
··
Genius Group (GNS) Soars on Market‑Manipulation Lawsuit: What Today’s 17 November 2025 Rally Really Means

Genius Group (GNS) Soars on Market‑Manipulation Lawsuit: What Today’s 17 November 2025 Rally Really Means

Genius Group shares jumped over 35% in U.S. pre-market trading Monday after the company filed a $250 million federal securities class action lawsuit against Citadel Securities and Virtu Americas. The stock later cooled to around $0.86 by midday, still up on heavy volume. The suit alleges widespread spoofing and naked short selling from 2022 to 2025.
17 November 2025
·
Dell Technologies (DELL) in Focus: AI Cloud Deal and Conflicting Analyst Calls – 17 Nov 2025

Dell Technologies (DELL) in Focus: AI Cloud Deal and Conflicting Analyst Calls – 17 Nov 2025

Dell shares swung sharply on November 17 after Morgan Stanley issued a rare double downgrade to Underweight and cut its price target to $110, citing higher memory costs. JPMorgan countered with a price target hike to $170 and added Dell to its “Positive Catalyst Watch.” Dell also announced a major AI cloud deal with HIVE Digital, aiming for over 6,000 new GPUs and $120 million in annual revenue by 2026.
17 November 2025
····
XPeng Stock (XPEV) Slides After Q3 2025 Earnings: Record Deliveries, Narrower Loss but Soft Q4 Guidance

XPeng Stock (XPEV) Slides After Q3 2025 Earnings: Record Deliveries, Narrower Loss but Soft Q4 Guidance

XPeng reported record Q3 2025 deliveries of 116,007 vehicles, up 149% year-on-year, with revenue doubling to RMB 20.38 billion and gross margin rising to 20.1%. Net loss narrowed to RMB 380 million, the smallest in five years. The company guided Q4 revenue below analyst expectations, citing fierce competition. Shares fell about 3% in pre-market trading.
17 November 2025
···
Apple CEO Succession 2026: Tim Cook’s Possible Exit, John Ternus’ Rise – and How Much Money Is on the Line

Apple CEO Succession 2026: Tim Cook’s Possible Exit, John Ternus’ Rise – and How Much Money Is on the Line

Apple’s board has accelerated CEO succession planning, with hardware chief John Ternus emerging as the leading internal candidate to replace Tim Cook, according to multiple reports citing the Financial Times. The transition could occur as early as 2026, with no announcement expected before Apple’s late-January earnings call. Cook, 65, is not being pushed out; Apple’s financial performance remains strong.
17 November 2025
·
Meta Platforms (META) November 2025 Stock Analysis: AI-Fueled Growth vs. Rising Costs

Meta Stock Today (META) – November 17, 2025: AI Spending Jitters, Buy‑the‑Dip Debate and the Latest META News

Meta Platforms traded near $609 on Monday, down over 23% from its August record high after a sharp selloff tied to ballooning AI capital spending plans of $70–72 billion for 2025. The company reported Q3 revenue of $51.2 billion but took a $15.9 billion tax charge, distorting earnings. Wall Street is split, with some firms increasing stakes while others trim holdings. Meta’s market cap stands near $1.5 trillion.
17 November 2025
·
QUBT Stock Today, November 17, 2025: Neurawave Launch and Q3 Earnings Put Quantum Computing Inc. Back in the Spotlight

QUBT Stock Today, November 17, 2025: Neurawave Launch and Q3 Earnings Put Quantum Computing Inc. Back in the Spotlight

Quantum Computing Inc. (NASDAQ: QUBT) shares rose about 6% to $10.60 early afternoon November 17 after announcing its Neurawave photonic computing platform ahead of SuperCompute25. The stock spiked up to 21% premarket before paring gains. QUBT cited triple-digit Q3 revenue growth and a surprise swing to GAAP profitability. Shares remain down roughly 35–40% year-to-date.
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks reported its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combinations outperformed trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The triple-combination arm also improved overall survival. Jazz Pharmaceuticals plans to file for FDA approval in the first half of 2026. ZYME shares jumped 30–50% pre-market on the news.
17 November 2025
····
1 … 1,525 1,526 1,527 1,528 1,529 … 1,861

Stock Market Today

  • West Pharmaceutical Services Q1 2026 Earnings Beat Estimates, Shares Surge
    April 23, 2026, 7:34 AM EDT. West Pharmaceutical Services (NYSE:WST) reported strong Q1 CY2026 results, with revenue rising 21% year-on-year to $844.9 million, exceeding analyst estimates by 8.4%. Adjusted earnings per share (EPS) came in at $2.13, beating forecasts by 27.1%. The company raised its full-year revenue guidance to $3.32 billion and adjusted EPS to $8.58. Operating margin improved to 21% from 15.3% last year. CEO Eric M. Green attributed growth to increased demand and successful production expansion, particularly in Europe. Despite a solid quarter, the company's longer-term revenue growth has moderated, with a 6.7% CAGR over five years and a slowdown to 4.9% in the past two years, raising some caution on future momentum.

Latest article

Heineken Beats Q1 Revenue Forecasts, Keeps 2026 Outlook Despite Beer Volume Dip

Heineken Beats Q1 Revenue Forecasts, Keeps 2026 Outlook Despite Beer Volume Dip

23 April 2026
Heineken reported a 2.8% rise in first-quarter organic net revenue, beating forecasts, but beer volumes fell 0.8% and shares dropped nearly 3%. Weakness persisted in Europe and the Americas, while Asia Pacific saw gains. The company kept its full-year profit outlook and gave no update on a successor to CEO Dolf van den Brink, who steps down May 31.
Tesla Q1 Earnings: Profit Beats Estimates on $22.4 Billion Revenue, but Musk’s Spending Surge Raises the Stakes

Tesla Q1 Earnings: Profit Beats Estimates on $22.4 Billion Revenue, but Musk’s Spending Surge Raises the Stakes

23 April 2026
Tesla reported first-quarter revenue of $22.39 billion and net income of $477 million, beating profit expectations despite weak vehicle deliveries and rising inventory. Adjusted earnings per share were 41 cents. Free cash flow reached $1.44 billion, but the company warned it would likely turn negative for the rest of 2026. Tesla increased its capital spending forecast to over $25 billion for the year.
Gold eases from one-week bounce as Iran truce holds and Warsh signals hawkish tilt

Gold eases from one-week bounce as Iran truce holds and Warsh signals hawkish tilt

23 April 2026
Gold fell 0.8% to $4,701/oz in early Asian trade Thursday, reversing much of Tuesday’s gain as an extended U.S.-Iran ceasefire reduced safe-haven demand. The dollar index rose to 98.57 and U.S. 10-year yields hit 4.31% after hawkish comments from Fed chair nominee Kevin Warsh. Gold remains about 13% below its January record high but is up 8% year-to-date. Traders await the April 28–29 FOMC meeting.
Go toTop